26 results about "Systemic circulation" patented technology

The invention discloses an artificial heart valve near-physiological pulsation fluid external evaluation device and method, and relates to the technical field of heart valve testing.The artificial heart valve near-physiological pulsation fluid external evaluation device comprises a supporting frame, a driving unit, a tested valve installation unit and an artery and peripheral loop unit, the driving unit provides power for liquid flowing, and the tested valve installation unit is used for fixing an artificial heart valve; and a liquid volume assembly and a resistance assembly of the artery and peripheral loop unit can simulate the compliance and resistance of aorta blood vessels and peripheral artery blood vessels, so that the pressure waveform simulation of the systemic circulation loop is more accurate. On the basis of the air cavity, the elastic corrugated pipes with different frequency responses are arranged, the compliance and rebound resilience of the aorta are simulated, a device for rapidly replacing the tested valve is designed, and the mechanical property of the simulated human body aorta is adjusted by adjusting the parameters such as the output frequency and the vibration amplitude of the driving unit; real pressure and flow waveforms under different physiological / pathological conditions are simulated, and a more accurate and convenient detection environment is realized.

The invention relates to a control method of auxiliary breathing equipment, a controller, equipment and a storage medium. The auxiliary breathing equipment comprises a first cavity, a second cavity, a pipeline assembly and a gas driving assembly. The method comprises the following steps: periodically acquiring detection information of intra-pulmonary pressure during the period of providing ventilation support by the auxiliary breathing equipment; in response to the fact that the detection information of the intra-pulmonary pressure exceeds a preset pressure range, pressure reduction operation or pressure increase operation is executed to adjust the intra-pulmonary pressure to be within the preset pressure range; the decompression operation comprises the steps that the pipeline assembly and the gas driving assembly are controlled, so that redundant gas in the lung is exhausted to the external environment through the second cavity in the process of maintaining partial gas circulation of the lung between the first cavity and the lung; the pressurization operation comprises the steps that the pipeline assembly and the gas driving assembly are controlled, so that gas of the breathing gas source is introduced into the lung through the first cavity in the process of maintaining partial gas circulation of the lung between the second cavity and the lung. The safety of ventilation support can be improved.

The invention relates to the technical field of medical health, and discloses a cardiopulmonary ultrasound assessment method and system for premature infant BPD early warning. The method comprises the steps that premature infant heart rate variability, pulmonary artery systolic pressure and respirator parameter data are synchronously collected through an HL7 FHIR protocol interface, and a BPD early warning basic data set is obtained; performing weighted fusion on the ratio of SDNN to RMSSD, the square ratio of pulmonary artery to systemic circulation systolic pressure and oxygenation parameters in the data through an algorithm to obtain a CPDI value; the CPDI and the cardiopulmonary parameters are combined to evaluate the pulmonary vascular resistance load, and a PVRL index is obtained; the CPDI, the PVRL, the gestational age and the body weight adjustment factor are fused, and a BPD occurrence risk score is obtained; and dividing risk levels according to the scoring interval and generating an early warning result. According to the method, the problem that premature infant BPD early warning lacks cardiopulmonary system multi-parameter fusion analysis and individualized risk assessment in the prior art is solved, and continuous dynamic early warning and accurate risk layering based on CPDI and PVRL indexes are achieved.

Methods and apparatus disclosed herein relate to graphical representation of patient hemodynamic state. In various embodiments, one or more measured physiological parameters of a patient may be analyzed. Based on the analysis, a graphical user interface (GUI) may be rendered. The GUI may include a figure-eight schematic (222, 1222) that represents a circulatory system of the patient. The figure-eight schematic may include: a first loop (224, 1224) that represents pulmonary circulation of the patient; a second loop (226, 1226) that represents systemic circulation of the patient; and a central object (228, 1228) that connects the first and second loops represents a heart of the patient. In various embodiments, each of the first and second loops includes multiple arc fragments, with each arc fragment being shaped to convey one or more of the measured physiological parameters of the patient.

The application provides an interventional ventricular auxiliary oxygen generation device, a blood flow channel crosses an aortic valve into a left ventricle from an ascending aorta, a blood inlet of the blood flow channel is located in the left ventricle, a blood outlet is located in the ascending aorta, a first conveying pipe and a second conveying pipe convey hydrogen peroxide and catalase into the left ventricle to generate oxygen and water through reaction, and a pumping unit pumps oxygen-rich blood in the left ventricle to the ascending aorta. The oxygen generation function is added to the ventricular auxiliary device, the oxygen-rich blood in the ventricle is pumped to the ascending aorta through the ventricular auxiliary device, which directly improves the myocardial hypoxia condition and helps the heart recover, and on the other hand, the oxygen-rich blood is pumped into the ascending aorta and directly participates in the systemic circulation, thereby directly and quickly improving the oxygen supply condition of the systemic circulation.

The invention relates to the technical field of medical instruments, in particular to an intrathoracic cardiac compression cardio-pulmonary resuscitation structure which comprises a case, an air supply part and a negative pressure part are fixedly mounted in the case, a storage box is fixedly connected to the inner wall of the case, and two hooks are integrally connected to the inner wall of the storage box. The storage box is fixedly connected with a sterile storage bag through the hook, a negative pressure pipeline, an air supply pipeline and an extrusion bag are stored in the sterile storage bag, one end of the air supply pipeline is used for being connected with an air supply part, and the other end of the air supply pipeline is used for being connected with the extrusion bag; one end of the negative pressure pipeline is used for being connected with the negative pressure part, and the other end of the negative pressure pipeline is used for being connected with the extrusion bag. The first air bag, the second air bag and the third air bag are used for carrying out partitioned extrusion on the heart, so that different pressure can be provided for systemic circulation and pulmonary circulation, and the physiological condition of a human body is better met.

The embodiment of the application discloses a kind of vein bionics microfluidic chip and its preparation and application method of simulating multi-organ interconnection.The chip includes a chip main body, and its microfluid channel system integrates at least three organ simulation units: a lung simulation chamber for culturing lung cells to simulate upstream organs that can produce systemic effects;An upstream colon cancer cell culture chamber for three-dimensional culture of colon cancer cells to simulate tumor primary lesions;And a downstream liver cell culture chamber for three-dimensional co-culture of liver cells and vascular endothelial cells to simulate the target organ of liver, and the three simulation chambers are communicated with each other by a vein bionics microfluid network, which simulates the complex blood circulation system of human body (including pulmonary circulation and systemic circulation), can realize the signal molecule transmission between organs, and simulate the invasion and metastasis process of colon cancer cells to the target organ of liver via the circulatory system after being affected by upstream lung signals.

The present application relates to the technical field of medicine, and particularly relates to an anti-pulmonary fibrosis prodrug compound and a preparation method and application thereof. The prodrug compound is a novel prodrug, and the structure comprises: a) an active drug unit selected from pirfenidone and nintedanib; b) a lung targeting unit selected from diphenyl chloroiodonium salt and a mimic thereof 521; and c) a linker unit which is a responsive linkage sensitive to a biomarker specifically overexpressed in a pulmonary fibrosis microenvironment. The prodrug is stable in the systemic circulation and has no activity or low activity, and can be actively targeted to a pulmonary fibrosis lesion; under the specific stimulation of the PFM, the linker is broken, and the original drug molecule is accurately released, so that the concentration of the drug in the lesion site is significantly increased, the toxic side effects caused by systemic exposure are reduced, and the anti-pulmonary fibrosis effect is enhanced.

The invention relates to an application of India giant globular bacteria in preparation of a medicine for regulating a tumor microenvironment, and belongs to the technical field of biological medicines. The invention provides an application of India giant globular bacteria XA-511 in preparation of a medicine for regulating a tumor microenvironment. Researches show that the India giant globular bacteria XA-511 can be colonized in a tumor microenvironment, the tumor microenvironment can be transformed through a metabolic pathway of the India giant globular bacteria XA-511, immune cell activation enhancement and the like, and cold tumors are transformed into hot tumors, so that the treatment effect of the immunosuppressor on tumors is promoted. Furthermore, treatment of secondary tumors is more difficult than primary tumors, since tumors may be present at multiple sites, and the volume and number of tumors may vary over time. And by virtue of the characteristic of a tumor hypoxia environment, the India giant globular bacteria XA-511 can be selectively colonized at a tumor occurrence part after entering a systemic circulatory system, so that the tumor microenvironment is specifically changed, and the treatment effect of the immunosuppressor on tumors is enhanced.

The present disclosure provides compositions and methods for the preparation and therapeutic use of vectorized antibodies, such as adeno-associated virus (AAV) vectors having viral genomes encoding one or more therapeutic antibodies or antibody fragments or antibody-like polypeptides having reduced stability outside of a tissue of interest. In some embodiments, the disclosure provides therapeutic antibodies comprising a sequence motif for increasing susceptibility of the therapeutic antibodies to protease degradation in systemic circulation. In some embodiments, the disclosure provides therapeutic antibodies comprising a variant Fc domain having reduced binding affinity to FcRn. The disclosure also provides use of the AAVs for the prevention and / or treatment of diseases and / or disorders of the central nervous system (CNS).

The application belongs to the technical field of medicine, and particularly relates to application of acacetin or 6-hydroxyflavone in preparation of anti-angina pectoris drugs, and aims to solve the problems of adverse reactions such as blood pressure drop, reflex tachycardia and the like caused by non-selective vasodilation of existing anti-angina pectoris drugs, wherein the drug improves myocardial blood supply by selectively dilating coronary vessels of the heart, wherein acacetin dilates coronary vessels of the heart by inhibiting cardiac coronary vessel myosin light chain kinase and activating myosin light chain phosphatase, and 6-hydroxyflavone dilates coronary vessels of the heart by inhibiting protein kinase C and enhancing myosin light chain phosphatase activity; and the acacetin or 6-hydroxyflavone significantly reduces the symptoms of myocardial ischemia of rats caused by isopropyl adrenaline, improves characteristic ECG abnormal changes of angina pectoris, does not affect heart rate and systemic blood pressure, and is safer, thereby providing a potential drug selection for anti-angina pectoris treatment.

This invention provides a systemic-pulmonary dual-circulation simulation system for testing the hemodynamic performance of an artificial heart. It includes a cardiovascular silicone model, a ventricular pulsation device, a controller, a data acquisition device, a fluid reservoir, and an artificial heart. The cardiovascular silicone model, ventricular pulsation device, and fluid reservoir are connected in series to form a blood circulation loop. The cardiovascular silicone model includes systemic and pulmonary circulation loops; the ventricular pulsation device has an internal electric cylinder that drives a piston to reciprocate via a push rod, causing fluid flow in the blood circulation loop; the controller controls the movement of the ventricular pulsation device to simulate blood flow with physiological pulsatile flow characteristics; the data acquisition device collects pressure and flow rate data at different locations on the cardiovascular silicone model. This invention can not only completely simulate the blood flow patterns of the human cardiovascular system but also be used to test the impact of artificial heart implantation on the hemodynamic performance of the human cardiovascular system under different physiological conditions, contributing to the development and research of artificial hearts.

A positive displacement pump that triggers with the beating of a mammalian heart, through the monitoring of an ECG signal is disclosed. A programmable delay from the detection of the forthcoming contraction of the heart enables the pump to syncopate the ejection of the fluid with the events occurring in the cardiovascular system. This delayed ejection could be used to overlay the ejected fluid from the pump with a pressure wave in the artery of systemic circulation through a catheter connection between the pump and a physiological model (e.g., cow, dog, human). The outcome of this use could be to raise the pulse pressure in the system to take advantage of physiological pathways that respond to this transient change in blood pressure. The novelty of this system stems from the adaptable control architecture designed to augment the pulsatile characteristics of the cardiovascular system. This inventive concept could be expanded to encompass the augmentation (dampen or enhance) of pulsatile characteristics in any oscillating flow system.

Provided herein are methods for delivering an agent (e.g., a therapeutic agent) preferentially to the heart, e.g., percutaneously, of a patient under conditions of cardiac arrest and isolation of cardiac circulation from systemic circulation. Also disclosed are methods of treating a cardiac condition in a patient using the methods of delivery.

The application is a catheter pump with oxygen supply function which can improve oxygen supply of body circulation, the proximal end of the motor is connected with the catheter, the distal end is coaxially connected with an impeller, the outer periphery cover of the impeller is provided with a blood outflow cage, the distal end of the blood outflow cage is fixed with the proximal end of a blood inflow cage through a sleeve, the distal end of the blood inflow cage is further connected with a pigtail tube, an oxygen supply unit is arranged on the blood outflow cage, the oxygen supply unit generates oxygen according to physiological signals collected by a sensing unit in the ascending aorta according to time and demand, and releases the oxygen into the blood in the ascending aorta. In the process of assisting the heart to pump blood, the catheter pump can simultaneously supplement oxygen into the blood by using the oxygen supply unit, and improve the hypoxia condition of the whole body tissue. The oxygen supply unit is integrated on the catheter pump, and the catheter pump is intervened through the blood vessel together with the oxygen supply unit, so that the operation is simple, the damage to the blood vessel is reduced, the risk of gas embolism is reduced, the oxygen is better distributed, the oxygen supply mode is more in line with the physiological state, and the recovery of the patient is facilitated.

This invention discloses a parameter identification method for a lumped parameter model of systemic circulation, belonging to the field of lumped parameter model technology. The method includes: constructing the state equation of the lumped parameter model of systemic circulation based on Kirchhoff's voltage and current laws to obtain the systemic circulation control equation; calculating the duration ratio of systolic to diastolic phases and stroke volume based on routine clinical measurement data, constructing classic aortic pressure and flow waveforms, and performing registration processing; calculating central venous pressure and flow based on routine clinical measurement data; and using the registered aortic inlet pressure and flow, central venous pressure and flow, and systemic circulation control equations to calculate the values ​​of each parameter in the parameter model. This invention, by periodically stretching the classic reference waveform, matches the waveform extreme values ​​with the patient's measured blood pressure and cardiac output, indirectly reconstructing the aortic inlet pressure and flow curve reflecting individual characteristics under non-invasive conditions, significantly improving the model's individualization and clinical compatibility.

Disclosed in certain embodiments is a parenteral formulation comprising a therapeutically effective amount of an emergency rescue active pharmaceutical ingredient and a parenterally acceptable adjuvant in an amount that enhances the absorption of the emergency rescue active pharmaceutical ingredient (ER-API) into the systemic circulation. The enhancement of absorption can be evidenced by a faster onset of action, a faster T max and / or a higher C max and / or a higher AUC last and / or a higher AUC 0.25 and / or a higher AUC 0.5 and / or a higher AUC 0.75 and / or a higher AUC1and / or increased bioavailability compared to a formulation without the adjuvant.

A right ventricular assist device (RVAD) (420) is provided that includes a pulsatile- flow pump (424) defining a pump chamber (426) that includes first and second sub- chambers (427A, 427B) in fluid isolation from each other. Proximal and distal cannulas (438, 432) are configured to be inserted into a right ventricle (450) and couplable to an artery (302) of the systemic circulation, respectively, and arranged in fluid communication with a proximal opening (428) of the first sub-chamber (427A) and a distal opening (430) of the second sub-chamber (427B), respectively. The pulsatile-flow pump (424) provides pulsatile flow synchronized with the cardiac cycle in a counterpulsation mode by, during at least a portion of ventricular diastole, pumping blood in a distal direction out of the distal opening (430) and drawing blood in the distal direction into the proximal opening (428); and during at least a portion of ventricular systole, pumping blood in the opposite direction. Other embodiments are also described.

A minimally invasive, small percutaneous mechanical circulatory support system delivers a pump transcatheterally to the heart, which actively reduces the burden on the left ventricular system by pumping blood from the left ventricle to the ascending aorta and then to the systemic circulation. The pump may include a tubular housing, a motor, an impeller configured to be rotated by the motor, and a distal tip of the pump. The tip may include a guidewire lumen having a curved and / or extended contour. The system may include an insertion tool having a tubular body and configured to receive the circulatory support device axially movable, and an introducer sheath configured to receive the insertion tool axially movable. A coupling allows for connection and disconnection between the insertion tool and the introducer sheath. The coupling may include a hexagonal portion for self-positioning and further for tactile feedback.

The application relates to a simulated lung for detecting a physiological closed-loop control function of a breathing machine, comprising a blood circulation system, in which blood circulates; a gas circulation system, in which oxygen circulates; the gas circulation system and the blood circulation system are independent of each other; a membrane oxygenator for realizing blood-oxygen exchange; the blood circulation system circulates blood through the membrane oxygenator, and the gas circulation system circulates oxygen through the membrane oxygenator; a data acquisition system connected with the blood circulation system at one end to realize blood data monitoring; and connected with the gas circulation system at the other end, wherein the gas circulation system adjusts ventilation according to the blood data. Compared with the prior art, the application combines the membrane oxygenator with the water-sealed simulated lung to detect the breathing machine with the PCLC function, so that the accuracy, reliability and safety of the breathing machine can be improved.

This invention discloses a systemic circulation venous simulation system, comprising a right ventricular simulation component, an arterial compliance simulation component, a venous vessel module, a damping module, a throttling valve, a collapsible venous segment, a venous compliance simulation component, a right atrial simulation component, a drive module, and a data acquisition module. The right ventricular simulation component simulates the pumping function of the right ventricle; the arterial compliance simulation component simulates the elastic energy storage characteristics of the arterial system; the venous vessel module includes a collecting chamber, a superior vena cava return vessel, an inferior vena cava return vessel, and a vena cava confluence conduit; the collapsible venous segment prevents excessive negative pressure in the venous system; the venous compliance simulation component reduces the impact of right atrial pressure fluctuations on the venous vessels; and the right atrial simulation component simulates the right atrial filling state through internal volume changes. This simulation system can be used for in vitro testing of vena cava intervention devices.

The application is a catheter pump with oxygenation function which can directly improve the myocardial hypoxia condition. The motor is connected with the catheter at the proximal end, and the impeller is coaxially connected at the distal end. The outer periphery of the impeller is covered with a blood outflow cage. The distal end of the blood outflow cage is fixed with the proximal end of the blood inflow cage through a sleeve. The distal end of the blood inflow cage is also connected with a pigtail tube. An oxygenation unit is arranged on the blood inflow cage. The oxygenation unit produces oxygen in the left ventricle according to the physiological signals collected by the sensing unit, and releases the oxygen into the blood in the left ventricle. The oxygenation unit enters the left ventricle with the blood inflow cage, directly produces oxygen in situ in the left ventricle, supplies oxygen to the blood in the left ventricle, rapidly improves the myocardial hypoxia condition, and promotes the recovery of the heart. The oxygenation unit is integrated on the catheter pump, and the catheter pump is intervened through the blood vessel together with the oxygenation unit, so that the operation is simple, and the damage to the blood vessel can be reduced. This oxygen supply mode can directly improve the myocardial hypoxia condition, and can also improve the aortic valve regurgitation condition and the oxygen supply condition of the systemic circulation.

Disclosed is a method for treating a renal condition by loco-regional perfusion of one or both of a patient's kidneys. A closed circuit may be formed with a perfusion catheter positioned in the renal artery of the kidney, a recovery catheter positioned in the renal vein of the kidney, and an external membrane oxygenator disposed therebetween. A perfusate containing, for example, a drug may be circulated through the closed circuit while isolating the closed circuit from the patient's systemic circulation.

A simplified method for determining liver function is provided based on a compartmental model (CM) approach for the analysis of various liver indices, including the cholate SHUNT test, which simultaneously and closely approximates and elucidates the fundamental physiology of hepatic uptake of cholate from the systemic and portal circulations.

The invention discloses a magnetic suspension total artificial heart and a self-adaptive flow regulation and control method thereof, and relates to the technical field of total artificial hearts.The method comprises the following regulation and control processes that multi-dimensional parameter information is sensed and collected in real time; carrying out physiological state evaluation and demand modeling; resolving by a self-adaptive control algorithm and adjusting the rotating speed; the magnetic suspension driving system dynamically executes the instruction; according to the invention, on the basis of the hardware architecture of the magnetic suspension full-artificial heart, the multi-parameter sensing module can collect pressure, flow and rotating speed signals in real time to realize accurate data input, and the control unit can construct a flow self-adaptive adjustment model based on physiological parameter changes, so that the flow self-adaptive adjustment can be realized. The rotating speeds of the left and right magnetic suspension blood pumps are dynamically adjusted through an adaptive algorithm, and the flow balance of systemic circulation and pulmonary circulation is maintained by dynamically, accurately and cooperatively adjusting the rotating speeds of the left and right blood pumps, so that the life quality and safety of a patient can be improved to the maximum extent.

The utility model relates to the technical field of medical equipment, in particular to high-stability first-aid pressing equipment which comprises a mounting plate, a driving motor and a fixed adjusting assembly. A fixing box is arranged at the upper end of the mounting plate, a fixing plate is arranged at the lower end of the mounting plate, and a fixing adjusting assembly is arranged on the inner side of the fixing plate; a driving motor is arranged on the inner side of the fixed box, a rotating shaft is arranged at the output end of the driving motor, a disc is arranged on the outer side of the rotating shaft, a movable block is arranged on the inner side of the disc, a first spring is arranged on the inner side of the movable block, a clamping block is arranged on one side of the first spring, and a first rotating block is arranged on one side of the clamping block; according to the device, the pressing frequency is quickly adjusted in a flexible adjusting mode, so that the problems that most of the pressing frequencies cannot be adjusted, the pressing frequency is too low, blood pumping of the heart cannot be effectively promoted, systemic circulation cannot be maintained, and if the pressing frequency is too high, the heart does not have enough time to be filled with blood, and the blood circulation cannot be maintained are solved. Therefore, the blood flow during the next pressing is influenced.